Skip to main content
Top
Published in: Internal and Emergency Medicine 2/2024

16-12-2023 | Colchicine | IM - ORIGINAL

Do we consider enough the presence of triggering factors in the evaluation of patients with FMF? Triggering factors are highly prevalent in colchicine-resistant FMF patients

Authors: Bayram Farisogullari, Levent Kilic, Gozde Kubra Yardimci, Ali Akdogan

Published in: Internal and Emergency Medicine | Issue 2/2024

Login to get access

Abstract

The aim of the study is to investigate the frequency of triggering factors in colchicine-resistant and -responsive Familial Mediterranean Fever (FMF) patients as well as the effect of  interleukin (IL)-1 antagonist treatment on the triggering factors. Both colchicine-resistant (patients on IL-1 antagonist treatment) and colchicine-responsive (patients on colchicine who had ≤ 3 attacks in the last year) patients were questioned for the presence of 12 different triggering factors, including exposure to cold, emotional stress, fatigue, physical activity, menstruation (for females), sleeplessness, prolonged standing, long-duration travel, high-fat diet intake, starvation, infection, and trauma. Colchicine-resistant patients were questioned for the presence of triggering factors for two time periods, before and after treatment with IL-1 antagonists. We studied 28 colchicine-resistant and 35 colchicine-responsive patients. Overall 77.8% of patients had at least one triggering factor. Triggering factors were associated with 28.5% of the total number of attacks. More than half of the patients (57.1%) declared that they had avoided these conditions. The frequency of triggering factors was higher in the colchicine-resistant group as compared to the colchicine-responsive group (89.3% vs 68.6%; p = 0.04). In colchicine-resistant FMF patients, the frequency of triggering factors (89.3% vs 32.1%) and the percentage of attacks initiated by triggering factors (27.8 vs 14.4%; p < 0.001) were decreased after treatment with IL-1 antagonists. In this study, triggering factors were more frequent in colchicine-resistant patients as compared to colchicine-responsive patients. Treatment with IL-1 antagonists seems to increase the endurance of colchicine-resistant patients in stressful conditions.
Literature
2.
go back to reference Ozen S, Demirkaya E, Erer B, Livneh A, Ben-Chetrit E, Giancane G et al (2016) EULAR recommendations for the management of familial Mediterranean fever. Ann Rheum Dis 75(4):644–651CrossRefPubMed Ozen S, Demirkaya E, Erer B, Livneh A, Ben-Chetrit E, Giancane G et al (2016) EULAR recommendations for the management of familial Mediterranean fever. Ann Rheum Dis 75(4):644–651CrossRefPubMed
4.
go back to reference Korkmaz C, Cansu DU, Cansu GB (2020) Familial Mediterranean fever: the molecular pathways from stress exposure to attacks. Rheumatology (Oxford) 59(12):3611–3621CrossRefPubMed Korkmaz C, Cansu DU, Cansu GB (2020) Familial Mediterranean fever: the molecular pathways from stress exposure to attacks. Rheumatology (Oxford) 59(12):3611–3621CrossRefPubMed
5.
go back to reference Karadag O, Tufan A, Yazisiz V, Ureten K, Yilmaz S, Cinar M et al (2013) The factors considered as trigger for the attacks in patients with familial Mediterranean fever. Rheumatol Int 33(4):893–897CrossRefPubMed Karadag O, Tufan A, Yazisiz V, Ureten K, Yilmaz S, Cinar M et al (2013) The factors considered as trigger for the attacks in patients with familial Mediterranean fever. Rheumatol Int 33(4):893–897CrossRefPubMed
6.
go back to reference Yenokyan G, Armenian HK (2012) Triggers for attacks in familial Mediterranean fever: application of the case-crossover design. Am J Epidemiol 175(10):1054–1061CrossRefPubMed Yenokyan G, Armenian HK (2012) Triggers for attacks in familial Mediterranean fever: application of the case-crossover design. Am J Epidemiol 175(10):1054–1061CrossRefPubMed
7.
go back to reference Hentgen V, Vinit C, Fayand A, Georgin-Lavialle S (2020) The use of interleukine-1 inhibitors in familial Mediterranean fever patients: a narrative review. Front Immunol 11:971CrossRefPubMedPubMedCentral Hentgen V, Vinit C, Fayand A, Georgin-Lavialle S (2020) The use of interleukine-1 inhibitors in familial Mediterranean fever patients: a narrative review. Front Immunol 11:971CrossRefPubMedPubMedCentral
8.
go back to reference Erden A, Batu ED, Sarı A, Sönmez HE, Armagan B, Demir S et al (2018) Which definition should be used to determine colchicine resistance among patients with familial Mediterranean fever? Clin Exp Rheumatol 36:97–102PubMed Erden A, Batu ED, Sarı A, Sönmez HE, Armagan B, Demir S et al (2018) Which definition should be used to determine colchicine resistance among patients with familial Mediterranean fever? Clin Exp Rheumatol 36:97–102PubMed
9.
go back to reference Babaoglu H, Armagan B, Bodakci E, Satis H, Atas N, Sari A et al (2021) Predictors of persistent inflammation in familial Mediterranean fever and association with damage. Rheumatology 60(1):333–339CrossRefPubMed Babaoglu H, Armagan B, Bodakci E, Satis H, Atas N, Sari A et al (2021) Predictors of persistent inflammation in familial Mediterranean fever and association with damage. Rheumatology 60(1):333–339CrossRefPubMed
10.
go back to reference Demirkaya E, Acikel C, Hashkes P, Gattorno M, Gul A, Ozdogan H et al (2016) Development and initial validation of international severity scoring system for familial Mediterranean fever (ISSF). Ann Rheum Dis 75(6):1051–1056CrossRefPubMed Demirkaya E, Acikel C, Hashkes P, Gattorno M, Gul A, Ozdogan H et al (2016) Development and initial validation of international severity scoring system for familial Mediterranean fever (ISSF). Ann Rheum Dis 75(6):1051–1056CrossRefPubMed
11.
go back to reference Skendros P, Papagoras C, Mitroulis I, Ritis K (2019) Autoinflammation: lessons from the study of familial Mediterranean fever. J Autoimmun 104:102305CrossRefPubMed Skendros P, Papagoras C, Mitroulis I, Ritis K (2019) Autoinflammation: lessons from the study of familial Mediterranean fever. J Autoimmun 104:102305CrossRefPubMed
12.
go back to reference Acer Kasman S, Duruoz MT (2022) Seasonal residual activity in adult familial Mediterranean fever: a longitudinal observational study. Rheumatol Int 42(9):1573–1578CrossRefPubMed Acer Kasman S, Duruoz MT (2022) Seasonal residual activity in adult familial Mediterranean fever: a longitudinal observational study. Rheumatol Int 42(9):1573–1578CrossRefPubMed
13.
go back to reference Avagyan T, Budumyan A, Hayrapetyan A, Tadevosyan A (2018) Influence of some environmental factors on manifestation of familial Mediterranean fever in children: clinical and genetic aspects. Caucaus J Health Sci Public health 2:1–5 Avagyan T, Budumyan A, Hayrapetyan A, Tadevosyan A (2018) Influence of some environmental factors on manifestation of familial Mediterranean fever in children: clinical and genetic aspects. Caucaus J Health Sci Public health 2:1–5
14.
go back to reference Kumei S, Nozu T, Ohira M, Miyagishi S, Okumura T (2017) Cold exposure related fever with an Mediterranean fever (MEFV) gene mutation. Intern Med 56(16):2233–2236CrossRefPubMedPubMedCentral Kumei S, Nozu T, Ohira M, Miyagishi S, Okumura T (2017) Cold exposure related fever with an Mediterranean fever (MEFV) gene mutation. Intern Med 56(16):2233–2236CrossRefPubMedPubMedCentral
15.
go back to reference Gidron Y, Berkovitch M, Press J (2003) Psychosocial correlates of incidence of attacks in children with familial Mediterranean fever. J Behav Med 26(2):95–104CrossRefPubMed Gidron Y, Berkovitch M, Press J (2003) Psychosocial correlates of incidence of attacks in children with familial Mediterranean fever. J Behav Med 26(2):95–104CrossRefPubMed
16.
go back to reference Kishida D, Nakamura A, Yazaki M, Oka K, Tsuchiya-Suzuki A, Ichikawa T et al (2020) Triggering factors for febrile attacks in Japanese patients with familial Mediterranean fever. Clin Exp Rheumatol 38 Suppl 127(5):76–79PubMed Kishida D, Nakamura A, Yazaki M, Oka K, Tsuchiya-Suzuki A, Ichikawa T et al (2020) Triggering factors for febrile attacks in Japanese patients with familial Mediterranean fever. Clin Exp Rheumatol 38 Suppl 127(5):76–79PubMed
17.
go back to reference Makay B, Emiroglu N, Unsal E (2010) Depression and anxiety in children and adolescents with familial Mediterranean fever. Clin Rheumatol 29(4):375–379CrossRefPubMed Makay B, Emiroglu N, Unsal E (2010) Depression and anxiety in children and adolescents with familial Mediterranean fever. Clin Rheumatol 29(4):375–379CrossRefPubMed
18.
go back to reference Onat AM, Öztürk MA, Özçakar L, Üreten K, Kaymak SU, Kiraz S et al (2007) Selective serotonin reuptake inhibitors reduce the attack frequency in familial mediterranean Fever. Tohoku J Exp Med 211(1):9–14CrossRefPubMed Onat AM, Öztürk MA, Özçakar L, Üreten K, Kaymak SU, Kiraz S et al (2007) Selective serotonin reuptake inhibitors reduce the attack frequency in familial mediterranean Fever. Tohoku J Exp Med 211(1):9–14CrossRefPubMed
19.
go back to reference Akar S, Soyturk M, Onen F, Tunca M (2006) The relations between attacks and menstrual periods and pregnancies of familial Mediterranean fever patients. Rheumatol Int 26(7):676–679CrossRefPubMed Akar S, Soyturk M, Onen F, Tunca M (2006) The relations between attacks and menstrual periods and pregnancies of familial Mediterranean fever patients. Rheumatol Int 26(7):676–679CrossRefPubMed
20.
go back to reference Schwabe AD, Peters RS (1974) Familial Mediterranean fever in Armenians. Analysis of 100 cases. Medicine 53(6):453–462CrossRefPubMed Schwabe AD, Peters RS (1974) Familial Mediterranean fever in Armenians. Analysis of 100 cases. Medicine 53(6):453–462CrossRefPubMed
21.
go back to reference Xu H, Yang J, Gao W, Li L, Li P, Zhang L et al (2014) Innate immune sensing of bacterial modifications of Rho GTPases by the Pyrin inflammasome. Nature 513(7517):237–241ADSCrossRefPubMed Xu H, Yang J, Gao W, Li L, Li P, Zhang L et al (2014) Innate immune sensing of bacterial modifications of Rho GTPases by the Pyrin inflammasome. Nature 513(7517):237–241ADSCrossRefPubMed
23.
go back to reference Ozturk MA, Kanbay M, Kasapoglu B, Onat AM, Guz G, Furst DE et al (2011) Therapeutic approach to familial Mediterranean fever: a review update. Clin Exp Rheumatol 29(4 Suppl 67):S77-86PubMed Ozturk MA, Kanbay M, Kasapoglu B, Onat AM, Guz G, Furst DE et al (2011) Therapeutic approach to familial Mediterranean fever: a review update. Clin Exp Rheumatol 29(4 Suppl 67):S77-86PubMed
Metadata
Title
Do we consider enough the presence of triggering factors in the evaluation of patients with FMF? Triggering factors are highly prevalent in colchicine-resistant FMF patients
Authors
Bayram Farisogullari
Levent Kilic
Gozde Kubra Yardimci
Ali Akdogan
Publication date
16-12-2023
Publisher
Springer International Publishing
Published in
Internal and Emergency Medicine / Issue 2/2024
Print ISSN: 1828-0447
Electronic ISSN: 1970-9366
DOI
https://doi.org/10.1007/s11739-023-03486-3

Other articles of this Issue 2/2024

Internal and Emergency Medicine 2/2024 Go to the issue
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.